Opvido 100mg

Generic Name – Nivolumab

Dosage form: Injection for intravenous infusion (100 mg/10 mL

Drug Class: Immune checkpoint inhibitors or PD-1 and PD-L1 inhibitors

Opdivo, generic name Nivolumab, is an immunotherapy treatment, prescribed for the treatment of varied cancer types like Melanoma, Non-small cell lung cancer, Renal cell carcinoma (kidney cancer), Urothelial carcinoma (bladder cancer), Squamous cell carcinoma of the head and neck, Classical Hodgkin lymphoma, Colorectal cancer in specific cases, and Esophageal and gastric cancers in selected treatment settings.

This injectable form is administered as an intravenous infusion every 2 to 4 weeks (Depending on cancer type). Opdivo (nivolumab) first gained FDA approval in 2014. This medicine is supplied as a concentrate for intravenous infusion.

The 100mg/10ml formulation contains nivolumab, which works by blocking the PD-1 (Programmed Death-1) receptor on T cells, a type of immune cell responsible for recognizing and attacking abnormal cells.

Under normal circumstances, certain cancer cells can use the PD-1 pathway to suppress immune activity and escape detection by the body’s defense system.

Opdivo blocks this pathway, helping T cells recognize and attack cancer cells more effectively. This medicine works by activating the body’s immune response rather than directly destroying cancer cells.

How Does Opdivo 100mg/10ml Work?

Opdivo 100mg/10ml or Nivolumab is a monoclonal antibody that blocks the PD-1 pathway. This injection form helps the immune system identify and attack cancer cells.

T-Cells or T-Lymphocytes are white cells. These cells help human body to identify and destroy abnormal cells.  Opdivo binds to PD-1 receptors on T-cells, preventing their interaction with PD-L1 and PD-L2 proteins. This action helps restore immune activity that certain cancers can suppress.

• By supporting the body’s natural immune response, this medicine can help the immune system fight cancer.
• However, its effects may also involve healthy tissues, potentially causing immune-related side effects.
• Opdivo is classified as an anti-PD-1 monoclonal antibody.
• Treatment suitability depends on the cancer type, clinical findings and relevant biomarker results.

Dosage of Opdivo 100mg/10ml :

Opdivo 100mg, referred to Opdivo 100mg/10ml (nivolumab) is an immunotherapy medicine used to treat certain types of cancer.

• This peptide is in injectable form and taken through an intravenous (IV) infusion, usually over 30 minutes.
• The prescribed dosage depends on the cancer type, treatment regimen, body weight, and individual response.
• For many adult cancer indications, Opdivo is given as 240mg every 2 weeks or 480mg every 4 weeks, although combination treatments may follow different schedules.
• For children and adolescents, dosing depends on the approved cancer indication, age, and body weight.

The oncologist will determine the appropriate dose and treatment schedule according to the patient’s medical needs. Opdivo 100mg should only be administered under specialist medical supervision.

Benefits of Using Opdivo 100mg/10ml :

Opdivo 100mg (nivolumab) is an immunotherapy medicine used to treat certain types of cancer.

It works by blocking the PD-1 protein on immune cells, helping the immune system recognize and attack cancer cells. Depending on the cancer type, disease stage, biomarker findings, and treatment eligibility, it may be prescribed alone or alongside chemotherapy or other anticancer medicines.

This drug blocks the PD-1 pathway, helping immune cells recognize and respond more effectively to cancer cells.

• Opdivo may help slow disease progression and improve treatment outcomes in eligible patients, depending on the cancer type and individual response.
• This drug may be prescribed for certain patients with non-small cell lung cancer, either alone or in combination with other anticancer treatments.
• This drug is used to treat certain forms of melanoma, including advanced disease and selected cases where treatment following surgery may help reduce the risk of recurrence.
• According to doctors, Opdivo may be used for eligible patients with renal cell carcinoma, either alone or alongside other medicines, according to the treatment plan.
• Opdivo may help manage recurrent or metastatic head and neck squamous cell carcinoma in patients who meet the relevant treatment criteria.
• on the approved indication, nivolumab may also be prescribed for selected cases of bladder cancer, colorectal cancer, esophageal cancer, stomach cancer, and other malignancies.
• This can be combined with chemotherapy, targeted medicines, or other immunotherapy agents for specific cancers when clinically appropriate.
• Some patients experience sustained responses to immunotherapy, although the duration and extent of benefit vary according to individual circumstances.

Opdivo 100 mg must be administered by qualified healthcare professionals under specialist supervision. Treatment requires monitoring for immune-related side effects, which can affect organs such as the lungs, liver, intestines, and endocrine glands.

Side Effects of Opdivo 100mg/10ml :

The possibility of mild to serious side effects cannot be ruled out during treatment with Opdivo 100mg/10ml. Some commonly reported side effects may include:

• Fatigue or unusual tiredness
• Pain in the stomach, muscles, bones, or joints
• Skin rash or itching, diarrhea, and fever
• Cough, reduced appetite, and shortness of breath
• Constipation, nausea, and decreased thyroid hormone levels

Children may experience a different pattern of side effects from adults, depending on their age and treatment. These may include fever, vomiting, headache, abdominal pain, and reduced white blood cell counts. Severe or persistent symptoms require prompt medical assessment.

Conclusion :

Opdivo 100mg/10ml is a prescription medicine used in cancer treatment, depending on its active ingredient and approved indication. Its suitability, dosage, and treatment schedule must be determined by a qualified specialist. Medical supervision and regular monitoring are essential to assess treatment response, manage potential side effects, and support patient safety throughout therapy.

Important Medical Warning :

Use any other product here strictly according to your doctor’s prescription. Follow your healthcare professional’s instructions regarding dosage, administration, and treatment duration. Do not self-medicate, change the dose, or discontinue treatment without consulting your doctor. This medication must be administered by qualified healthcare professionals.